Testing a new injection to help severe lung disease patients breathe better

Plain-English translation of NCT06961214 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called to see if it can help people with moderate to severe COPD who are still having breathing problems despite taking standard inhalers. COPD is a chronic lung disease that makes it hard to breathe, and some patients continue to experience frequent flare-ups. The study will compare this new medication to a placebo (inactive treatment) to see if it reduces symptoms and flare-ups when added to your regular inhaler therapy.

Even when patients with COPD take their standard inhalers regularly, many still struggle with frequent flare-ups and poor breathing. This medication aims to fill that gap by targeting a specific type of immune response that may be making breathing worse for some patients.

Do you qualify?

You likely qualify if…

you are between 40 and 80 years old
you have been diagnosed with moderate to severe COPD for at least one year
you have had at least two moderate flare-ups or one severe flare-up in the past 12 months
you have a history of smoking (at least 10 pack-years) and are either still smoking or have quit
you have been taking the standard three-part inhaler therapy (steroid, long-acting bronchodilators) for at least 6 months
you have elevated eosinophil counts in your blood

You likely don't qualify if…

you have been diagnosed with asthma or another significant lung disease besides COPD
you have had a lung infection, pneumonia, or COPD flare-up in the past 4 weeks
you require supplemental oxygen for more than 12 hours per day
you have severe heart problems, right heart failure, or severe pulmonary high blood pressure
you have a parasitic infection or have had one in the past 6 months

What participation looks like

If you enroll, you will receive either the new medication or a placebo as a subcutaneous injection (a shot under the skin), in addition to continuing your regular inhalers. You will be randomly assigned to one of these two groups, and neither you nor the study staff will know which one you received. You will visit the clinic multiple times for breathing tests, blood work, and check-ins to see how you are doing and whether you are experiencing fewer flare-ups.

AI-generated summary from trial data · Jun 17, 2026 · Not medical advice

Trial locations(159 sites)

United States

GSK Investigational Site, Sheffield, Alabama

GSK Investigational Site, Aurora, Colorado

GSK Investigational Site, Brooksville, Florida

GSK Investigational Site, Doral, Florida

GSK Investigational Site, Fort Lauderdale, Florida